重型创伤性脑损伤非存活患者血清可溶性Fas配体水平升高
这项在5个ICU开展的前瞻性观察研究纳入重型孤立性TBI患者(GCS<9分且非颅脑损伤部位ISS<10分),于伤后第1天检测血清sFasL浓度。sFasL预测死亡的AUC为75%(95%CI 63%-87%);sFasL>29.2 pg/mL者死亡率更高(HR=6.2,95%CI 2.6-14.8)。控制GCS、年龄和CT表现后(OR=1.055)及控制APACHE-II、ICP和CT表现后(OR=1.048),sFasL仍与死亡相关。作者结论为该关联是主要新发现,未来需验证。
要点
- 重型孤立性TBI(GCS<9分且非颅脑部位ISS<10分)患者第1天血清sFasL>29.2 pg/mL者30天死亡率显著更高(HR=6.2,95%CI 2.6-14.8,P<0.001)。
- 血清sFasL预测30天死亡的AUC为75%(95%CI 63%-87%,P<0.001),仅为中等 discriminative 能力,不能单独作为决策依据。
- 多因素校正GCS、年龄、CT表现后sFasL与死亡相关(OR=1.055,95%CI 1.018-1.094,P=0.004)。
- 多因素校正APACHE-II、ICP、CT表现后sFasL仍与死亡相关(OR=1.048,95%CI 1.017-1.080,P=0.002)。
适用人群与场景
- 重型孤立性创伤性脑损伤患者,定义为GCS<9分且非颅脑损伤部位ISS<10分,伤后第1天检测血清sFasL。
- 研究场景为5个ICU的前瞻性观察研究,原文未提及急诊或院前场景的适用性。
诊断标准与关键阈值
- 重型孤立性TBI定义:GCS<9分且非颅脑损伤部位ISS<10分。
- 血清sFasL>29.2 pg/mL为原文Kaplan-Meier分析中区分死亡率升高的界值(HR=6.2,95%CI 2.6-14.8,P<0.001),非诊断标准或决策阈值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性观察研究,5个ICU,纳入重型孤立性TBI患者,30天存活者n=59、非存活者n=24。
- 主要结果:非存活者较存活者血清sFasL更高(P<0.001);sFasL预测30天死亡的AUC为75%(95%CI 63%-87%,P<0.001)。
- Kaplan-Meier分析:sFasL>29.2 pg/mL者死亡率更高(HR=6.2,95%CI 2.6-14.8,P<0.001)。
- 多因素logistic回归:控制GCS、年龄和CT表现后sFasL与死亡相关(OR=1.055,95%CI 1.018-1.094,P=0.004);控制APACHE-II、ICP和CT表现后仍相关(OR=1.048,95%CI 1.017-1.080,P=0.002)。
- 组间比较:非存活者GCS更低(P=0.001)、年龄更大(P=0.004)、APACHE-II更高(P<0.001)、ICP更高(P=0.01)、CT高危表现更多(P=0.02)、sFasL更高(P<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性观察研究(非RCT),原文未给出证据等级或推荐强度。
对床旁实践的改变
- 原文提示血清sFasL可能作为重型孤立性TBI患者30天死亡的预后标志物,但作者明确需未来验证,不能据此改变现有抢救或ICU决策。
- AUC 75%属中等预测能力,且界值29.2 pg/mL来自单研究Kaplan-Meier分析,不宜作为临床决策阈值;原文未提供治疗干预建议。
指南或共识出处
- 原文未提及指南或共识;本文为发表于Neurocrit Care的研究论文。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Soluble Fas Ligand (sFasL) is one of the main ligands that activates the apoptosis extrinsic pathway. Higher expression of FasL in brain samples and higher cerebrospinal fluid FasL concentrations in traumatic brain injury (TBI) patients than in controls have been found. However, the potential association between blood sFasL concentrations and TBI mortality has not been reported. Therefore, the objective of this study was to determine whether that association exists.
METHODS: We included patients with a severe isolated TBI, defined as < 9 points in Glasgow Coma Scale (GCS) and < 10 non-cranial aspects points in Injury Severity Score in this observational and prospective study performed in 5 Intensive Care Units. We measured serum sFasL concentrations on day 1 of TBI.
RESULTS: We found that 30-day survivor (n = 59) in comparison to non-survivor patients (n = 24) had higher GCS (p = 0.001), lower age (p = 0.004), lower APACHE-II score (p < 0.001), lower intracranial pressure (ICP) (p = 0.01), lower computer tomography (CT) findings of high risk of death (p = 0.02) and lower serum sFasL concentrations (p < 0.001). The area under the curve for mortality prediction by serum sFasL levels was of 75% (95% CI = 63%-87%; p < 0.001). In Kaplan-Meier analysis was found that patients with serum sFasL levels > 29.2 pg/mL had a higher mortality rate (Hazard ratio = 6.2; 95% CI = 2.6-14.8; p < 0.001). Multiple logistic regression analysis found an association between serum sFasL levels and mortality after controlling for GCS, age and CT findings (OR = 1.055; 95% CI = 1.018-1.094; p = 0.004), and after controlling for APACHE-II, ICP and CT findings (OR = 1.048; 95% CI = 1.017-1.080; p = 0.002).
CONCLUSIONS: The association between serum sFasL levels and 30-day mortality in TBI patients was the major novel finding of our study; however, future validation could be interesting to confirm those results.
参考来源
- Lorente L, Martín MM, Pérez-Cejas A, et al. High Serum Soluble Fas Ligand Levels in Non-survivor Traumatic Brain Injury Patients. Neurocrit Care. 2021. PMID: 33403586. doi:10.1007/s12028-020-01158-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。